Rakesh Popat, Sagar Lonial, Peter M Voorhees, Simona Degli Esposti, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sandhya Sapra, Trisha Piontek, Zangdong He, David Kleinman, Debra Schaumberg, Antoine Regnault, Juliette Meunier, Laurie Eliason
In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patient-reported outcomes (PROs) from this study for patients treated with the approved dose of belantamab mafodotin (2.5 mg/kg q3w). Disease and treatment-related symptoms, health-related quality of life (HRQOL), functioning, and patient-reported ocular changes were assessed using questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life questionnaires EORTC-QLQ-C30 and EORTC-QLQ-MY20, Ocular Surface Disease Index [OSDI], and the National Eye Institute Visual Functioning Questionnaire 25 [NEI VFQ-25]) at baseline, during treatment (every 3 or 6 weeks), and at the end of treatment (EOT)...
September 2023: Journal of the Advanced Practitioner in Oncology